| Nadine P Wenner, MD | |
|
3455 Main St, Ste 5, Springfield, MA 01107-1147 | |
| (413) 733-9600 | |
| (413) 732-6534 |
| Full Name | Nadine P Wenner |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Location | 3455 Main St, Springfield, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144227703 | NPI | - | NPPES |
| 484187J597 | Other | CT | CONNECTICARE |
| 070004064 | Other | RAILROAD MEDICARE | |
| 17641 | Other | MA | HEALTH NEW ENGLAND |
| WEN51739 | Other | MA | BLUE CROSS BLUE SHIELD |
| 0304209 | Other | UNITED HEALTH CARE | |
| 071759 | Other | MA | TUFTS HEALTH PLANS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 71759 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Nadine P Wenner, MD 3455 Main St, Ste 5, Springfield, MA 01107-1147 Ph: (413) 733-9600 | Nadine P Wenner, MD 3455 Main St, Ste 5, Springfield, MA 01107-1147 Ph: (413) 733-9600 |
News Archive
Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of Glial Growth Factor 2 (GGF2). Acorda is collaborating with the Vanderbilt University Heart and Vascular Institute to conduct this Phase 1 single-dose trial in patients with heart failure.
Patients taking losmapimod, an anti-inflammatory drug currently being developed, for 12 weeks following a heart attack did not show improvements in the trial's primary endpoint, the rate of cardiovascular death, subsequent heart attack or urgent coronary revascularization, which includes placement of a stent or coronary artery bypass surgery, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.
The University of Alabama at Birmingham Comprehensive Cancer Center has received a five-year, $27.5 million Cancer Center Support Grant from the National Cancer Institute to renew support for its cancer research program through 2016.
PolyTherics Limited, a provider of solutions to enable the development of better biopharmaceuticals, and Spirogen Limited, a leading oncology-focused company developing DNA sequence-targeted agents, announce that they have formed a research collaboration to develop antibody drug conjugates that combine PolyTherics' proprietary site-specific conjugation chemistry with Spirogen's highly potent novel cytotoxic drugs to produce novel ADCs for the treatment of cancer.
› Verified 3 days ago
Michael Loosemore, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3455 Main St Ste 5, New England Dermatology & Laser Center, Springfield, MA 01107 Phone: 413-733-9600 Fax: 413-732-6534 | |
Sheila Greenlaw, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3455 Main St Ste 5, New England Dermatology & Laser Center, Springfield, MA 01107 Phone: 413-733-9600 Fax: 413-732-6534 | |
Dr. Michael D Horwich, MD, PHD Dermatology Medicare: Medicare Enrolled Practice Location: 3455 Main St Ste 5, New England Dermatology & Laser Center, Springfield, MA 01107 Phone: 413-733-9600 Fax: 413-732-6534 | |
David Wartman, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3455 Main St, Ste. # 5, Springfield, MA 01107 Phone: 413-733-9600 Fax: 413-732-6534 | |
Mark A Blumberg, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3455 Main St, Suite 5, Springfield, MA 01107 Phone: 413-733-9600 Fax: 413-732-6534 | |
Dr. Peter T Demos, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 125 Liberty St, Ste 403, Springfield, MA 01103 Phone: 413-739-6611 |